Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

GIST × pazopanib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 60 Sarcoma 38 Neoplasms 20 Neoplasm Metastasis 20 Breast Neoplasms 17 Ovarian Neoplasms 15 Carcinoma, Non-Small-Cell Lung 13 Melanoma 6 Leiomyosarcoma 6 Kidney Neoplasms 6 Hemangiosarcoma 6 Thyroid Neoplasms 5 Recurrence 5 Lung Neoplasms 5 Liposarcoma 5 Glioblastoma 5 Fallopian Tube Neoplasms 5 Urinary Bladder Neoplasms 4 Prostatic Neoplasms 4 Pancreatic Neoplasms 4 Osteosarcoma 4 Neurofibrosarcoma 4 Clear-cell metastatic renal cell carcinoma 4 Chondrosarcoma, Extraskeletal Myxoid 4 Uterine Cervical Neoplasms 3 Solid Tumors 3 Sarcoma, Synovial 3 Sarcoma, Alveolar Soft Part 3 Neuroendocrine Tumors 3 Histiocytoma, Malignant Fibrous 3

Interventions

vandetanib 1 pazopanib 1 olverembatinib 1 lenvatinib 1 avapritinib 1 Surgical Procedures, Operative 1 Imatinib Mesylate 1 Coal Tar 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01323400 2016-02-25

PAZOGIST

Centre Leon Berard

Phase 2 Completed

GIST

Data powered by HemOnc (CC BY 4.0) Colophon ⚡